Tags

Type your tag names separated by a space and hit enter

[18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.
Addict Biol. 2012 Mar; 17(2):490-503.AB

Abstract

Positron emission tomography (PET) shows reduced binding of the dopamine D(2/3) antagonist [(11) C]raclopride in striatum of withdrawn psychostimulant abusers, but not consistently in patients with alcohol dependence (AD). We make first use of the high affinity ligand [(18) F]fallypride to obtain serial measures of D(2/3) receptor availability in striatal and extrastriatal regions of AD patients undergoing detoxification. Seventeen patients (mean age 44 ± 5y) with AD and 14 age-matched healthy volunteers participated. Each patient underwent [(18) F]fallypride PET upon hospital admission, and again 1-2 weeks later; two patients achieving abstinence, and two with substantial harm reduction had additional PET follow-up at 1 year. Dynamic 180-minute PET recordings were used for volume of interest (VOI)-based and voxel-wise analysis of [(18) F]fallypride binding potential (BP(ND)). Mean baseline BP(ND) in striatum of the AD patients (15.7 ± 3.6) was unaltered during short-term follow-up, and did not differ from that in healthy controls (16.8 ± 3.0); however, BP(ND) was 10-20% lower in thalamus, hippocampus, and insular and temporal cortex of the AD patients (P < 0.05). Age-dependent declines in BP(ND) were very small in controls, but more pronounced and widespread in the AD group. Striatal and thalamic BP(ND) increased by 30% in four patients with long-term abstinence or reduced alcohol consumption. VOI-based [(18) F]fallypride PET analyses revealed group differences in D(2/3) receptor availability primarily in extra-striatal regions. Age-related loss of dopamine D(2/3) receptors was more pronounced in AD patients. Receptor availability was unaltered by acute withdrawal, but increased in the subgroup of patients with long-term follow-up, suggesting reversibility of receptor changes.

Authors+Show Affiliations

Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Germany. axel.rominger@med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22023291

Citation

Rominger, Axel, et al. "[18F]Fallypride PET Measurement of Striatal and Extrastriatal Dopamine D 2/3 Receptor Availability in Recently Abstinent Alcoholics." Addiction Biology, vol. 17, no. 2, 2012, pp. 490-503.
Rominger A, Cumming P, Xiong G, et al. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. Addict Biol. 2012;17(2):490-503.
Rominger, A., Cumming, P., Xiong, G., Koller, G., Böning, G., Wulff, M., Zwergal, A., Förster, S., Reilhac, A., Munk, O., Soyka, M., Wängler, B., Bartenstein, P., la Fougère, C., & Pogarell, O. (2012). [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. Addiction Biology, 17(2), 490-503. https://doi.org/10.1111/j.1369-1600.2011.00355.x
Rominger A, et al. [18F]Fallypride PET Measurement of Striatal and Extrastriatal Dopamine D 2/3 Receptor Availability in Recently Abstinent Alcoholics. Addict Biol. 2012;17(2):490-503. PubMed PMID: 22023291.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. AU - Rominger,Axel, AU - Cumming,Paul, AU - Xiong,Guoming, AU - Koller,Gabriele, AU - Böning,Guido, AU - Wulff,Melanie, AU - Zwergal,Andreas, AU - Förster,Stefan, AU - Reilhac,Anthonin, AU - Munk,Ole, AU - Soyka,Michael, AU - Wängler,Björn, AU - Bartenstein,Peter, AU - la Fougère,Christian, AU - Pogarell,Oliver, Y1 - 2011/10/03/ PY - 2011/10/26/entrez PY - 2011/10/26/pubmed PY - 2012/5/9/medline SP - 490 EP - 503 JF - Addiction biology JO - Addict Biol VL - 17 IS - 2 N2 - Positron emission tomography (PET) shows reduced binding of the dopamine D(2/3) antagonist [(11) C]raclopride in striatum of withdrawn psychostimulant abusers, but not consistently in patients with alcohol dependence (AD). We make first use of the high affinity ligand [(18) F]fallypride to obtain serial measures of D(2/3) receptor availability in striatal and extrastriatal regions of AD patients undergoing detoxification. Seventeen patients (mean age 44 ± 5y) with AD and 14 age-matched healthy volunteers participated. Each patient underwent [(18) F]fallypride PET upon hospital admission, and again 1-2 weeks later; two patients achieving abstinence, and two with substantial harm reduction had additional PET follow-up at 1 year. Dynamic 180-minute PET recordings were used for volume of interest (VOI)-based and voxel-wise analysis of [(18) F]fallypride binding potential (BP(ND)). Mean baseline BP(ND) in striatum of the AD patients (15.7 ± 3.6) was unaltered during short-term follow-up, and did not differ from that in healthy controls (16.8 ± 3.0); however, BP(ND) was 10-20% lower in thalamus, hippocampus, and insular and temporal cortex of the AD patients (P < 0.05). Age-dependent declines in BP(ND) were very small in controls, but more pronounced and widespread in the AD group. Striatal and thalamic BP(ND) increased by 30% in four patients with long-term abstinence or reduced alcohol consumption. VOI-based [(18) F]fallypride PET analyses revealed group differences in D(2/3) receptor availability primarily in extra-striatal regions. Age-related loss of dopamine D(2/3) receptors was more pronounced in AD patients. Receptor availability was unaltered by acute withdrawal, but increased in the subgroup of patients with long-term follow-up, suggesting reversibility of receptor changes. SN - 1369-1600 UR - https://www.unboundmedicine.com/medline/citation/22023291/[18F]Fallypride_PET_measurement_of_striatal_and_extrastriatal_dopamine_D_2/3_receptor_availability_in_recently_abstinent_alcoholics_ L2 - https://doi.org/10.1111/j.1369-1600.2011.00355.x DB - PRIME DP - Unbound Medicine ER -